The total number of records retrieved from this search are 90. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_729	Virus nameAdenovirus	Virus strainAdAFPp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationThe viral mutant with E1A gene driven by AFP promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to HL-7702 cell line	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result97% cancer cell viability on day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327
IDOV_731	Virus nameAdenovirus	Virus strainAdAFPp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationThe viral mutant with E1A gene driven by AFP promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to HL-7702 cell line	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result52% cancer cell viability on day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327
IDOV_733	Virus nameAdenovirus	Virus strainAdAFPp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationThe viral mutant with E1A gene driven by AFP promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to HL-7702 cell line	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result33% cancer cell viability on day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327
IDOV_735	Virus nameAdenovirus	Virus strainAdTrack	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result100% cancer cell viability on day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327
IDOV_737	Virus nameAdenovirus	Virus strainAdTrack	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result100% cancer cell viability on day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327
IDOV_739	Virus nameAdenovirus	Virus strainAdTrack	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result100% cancer cell viability on day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327
IDOV_741	Virus nameAdenovirus	Virus strainAdAFPp-E1A-122	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationThe viral insertion mutant with miR-122 target sequence into AdAFPp-E1A for negatively regulating E1A gene expression	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2 with mimics	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to HL-7702 cell line	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result80% cancer cell viability on day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327
IDOV_742	Virus nameAdenovirus	Virus strainAdAFPp-E1A-122	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationThe viral insertion mutant with miR-122 target sequence into AdAFPp-E1A for negatively regulating E1A gene expression	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2 with negative control	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to HL-7702 cell line	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result50% cancer cell viability on day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327
IDOV_743	Virus nameAdenovirus	Virus strainAdAFPp-E1A-122	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationThe viral insertion mutant with miR-122 target sequence into AdAFPp-E1A for negatively regulating E1A gene expression	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2 with mimics	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to HL-7702 cell line	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result65% cancer cell viability on day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327
IDOV_744	Virus nameAdenovirus	Virus strainAdAFPp-E1A-122	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationThe viral insertion mutant with miR-122 target sequence into AdAFPp-E1A for negatively regulating E1A gene expression	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2 with negative control	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to HL-7702 cell line	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result45% cancer cell viability on day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327
IDOV_745	Virus nameAdenovirus	Virus strainAdAFPp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationThe viral mutant with E1A gene driven by AFP promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2 with mimics	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to HL-7702 cell line	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result61% cancer cell viability on day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327
IDOV_746	Virus nameAdenovirus	Virus strainAdAFPp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationThe viral mutant with E1A gene driven by AFP promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2 with negative control	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to HL-7702 cell line	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result61% cancer cell viability on day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327
IDOV_747	Virus nameAdenovirus	Virus strainAdAFPp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationThe viral mutant with E1A gene driven by AFP promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2 with mimics	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to HL-7702 cell line	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result46% cancer cell viability on day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327
IDOV_748	Virus nameAdenovirus	Virus strainAdAFPp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationThe viral mutant with E1A gene driven by AFP promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College (PUMC), Tianjin, China	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2 with negative control	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to HL-7702 cell line	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result46% cancer cell viability on day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327
IDOV_1354	Virus nameAdenovirus	Virus strainCNHK300	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18300357
IDOV_1355	Virus nameAdenovirus	Virus strainCNHK300	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result90% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18300357
IDOV_1356	Virus nameAdenovirus	Virus strainCNHK300	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result20% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18300357
IDOV_1357	Virus nameAdenovirus	Virus strainCNHK300	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result20% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18300357
IDOV_1358	Virus nameAdenovirus	Virus strainCNHK300	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro resultless than 20% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18300357
IDOV_1359	Virus nameAdenovirus	Virus strainCNHK300	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1000 MOI	In-vitro resultless than 20% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18300357
IDOV_1916	Virus nameAdenovirus	Virus strainSG600-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of gene encoding IL24	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineInstitute of HCC, Fudan university	Origin of cell lineHuman liver cancer cell line	Cell lineHepG2	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result90% cell viabilty after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce the apoptosis in HCC cell line	Immunogenic effectNA	Clinical trialNA	PMID20872968
IDOV_1917	Virus nameAdenovirus	Virus strainSG600-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of gene encoding IL24	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineInstitute of HCC, Fudan university	Origin of cell lineHuman liver cancer cell line	Cell lineHepG2	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result70% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce the apoptosis in HCC cell line	Immunogenic effectNA	Clinical trialNA	PMID20872968
IDOV_1918	Virus nameAdenovirus	Virus strainSG600-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of gene encoding IL24	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineInstitute of HCC, Fudan university	Origin of cell lineHuman liver cancer cell line	Cell lineHepG2	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result60% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce the apoptosis in HCC cell line	Immunogenic effectNA	Clinical trialNA	PMID20872968
IDOV_1919	Virus nameAdenovirus	Virus strainSG600-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of gene encoding IL24	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineInstitute of HCC, Fudan university	Origin of cell lineHuman liver cancer cell line	Cell lineHepG2	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result30% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce the apoptosis in HCC cell line	Immunogenic effectNA	Clinical trialNA	PMID20872968
IDOV_1928	Virus nameAdenovirus	Virus strainSG600-EGFP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of gene encoding EGFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing EGFP gene	Source of cell lineInstitute of HCC, Fudan university	Origin of cell lineHuman liver cancer cell line	Cell lineHepG2	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result90% cell viabilty after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce the apoptosis in HCC cell line	Immunogenic effectNA	Clinical trialNA	PMID20872968
IDOV_1929	Virus nameAdenovirus	Virus strainSG600-EGFP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of gene encoding EGFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing EGFP gene	Source of cell lineInstitute of HCC, Fudan university	Origin of cell lineHuman liver cancer cell line	Cell lineHepG2	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result80% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce the apoptosis in HCC cell line	Immunogenic effectNA	Clinical trialNA	PMID20872968
IDOV_1930	Virus nameAdenovirus	Virus strainSG600-EGFP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of gene encoding EGFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing EGFP gene	Source of cell lineInstitute of HCC, Fudan university	Origin of cell lineHuman liver cancer cell line	Cell lineHepG2	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result70% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce the apoptosis in HCC cell line	Immunogenic effectNA	Clinical trialNA	PMID20872968
IDOV_1931	Virus nameAdenovirus	Virus strainSG600-EGFP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of gene encoding EGFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing EGFP gene	Source of cell lineInstitute of HCC, Fudan university	Origin of cell lineHuman liver cancer cell line	Cell lineHepG2	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result65% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce the apoptosis in HCC cell line	Immunogenic effectNA	Clinical trialNA	PMID20872968
IDOV_2114	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of AFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.1 MOI	In-vitro resultSome cell death observed	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID21979578
IDOV_2115	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of AFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro resultSome cell death observed	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID21979578
IDOV_2116	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of AFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro resultMost of the cells are died	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID21979578
IDOV_2117	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of AFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration100 MOI	In-vitro resultMost of the cells are died	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID21979578
IDOV_2134	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of TRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.1 MOI	In-vitro resultSome cell death observed	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID21979578
IDOV_2135	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of TRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro resultSome cell death observed	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID21979578
IDOV_2136	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of TRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro resultSome cell death observed	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID21979578
IDOV_2137	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of TRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration100 MOI	In-vitro resultMost of the cells are died	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID21979578
IDOV_2537	Virus nameAdenovirus	Virus strainAD55-Apoptin	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of Apoptin gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result90% cells viable after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID22321574
IDOV_2538	Virus nameAdenovirus	Virus strainAD55-Apoptin	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of Apoptin gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result80% cells viable after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID22321574
IDOV_2539	Virus nameAdenovirus	Virus strainAD55-Apoptin	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of Apoptin gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result70% cells viable after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID22321574
IDOV_2540	Virus nameAdenovirus	Virus strainAD55-Apoptin	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of Apoptin gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result60% cells viable after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID22321574
IDOV_2554	Virus nameAdenovirus	Virus strainSG600-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of IL-24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line1000 cells	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result90.2% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombined therapy increases STAT1, SOCS1 and apoptosis	Immunogenic effectCombined therapy decreases expression of MMP-2, XIAP,OPN and VEGF	Clinical trialNA	PMID22569271
IDOV_2555	Virus nameAdenovirus	Virus strainSG600-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of IL-24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line1000 cells	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result70.3% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombined therapy increases STAT1, SOCS1 and apoptosis	Immunogenic effectCombined therapy decreases expression of MMP-2, XIAP,OPN and VEGF	Clinical trialNA	PMID22569271
IDOV_2556	Virus nameAdenovirus	Virus strainSG600-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of IL-24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line1000 cells	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result56.2% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombined therapy increases STAT1, SOCS1 and apoptosis	Immunogenic effectCombined therapy decreases expression of MMP-2, XIAP,OPN and VEGF	Clinical trialNA	PMID22569271
IDOV_2557	Virus nameAdenovirus	Virus strainSG600-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of IL-24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line1000 cells	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result25.3% cell survival after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombined therapy increases STAT1, SOCS1 and apoptosis	Immunogenic effectCombined therapy decreases expression of MMP-2, XIAP,OPN and VEGF	Clinical trialNA	PMID22569271
IDOV_2558	Virus nameAdenovirus	Virus strainSG600-IL-24+IFN	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of IL-24 gene and addition of IN	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene and IFN gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line1000 cells	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result88.3% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombined therapy increases STAT1, SOCS1 and apoptosis	Immunogenic effectCombined therapy decreases expression of MMP-2, XIAP,OPN and VEGF	Clinical trialNA	PMID22569271
IDOV_2559	Virus nameAdenovirus	Virus strainSG600-IL-24+IFN	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of IL-24 gene and addition of IN	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene and IFN gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line1000 cells	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result64% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombined therapy increases STAT1, SOCS1 and apoptosis	Immunogenic effectCombined therapy decreases expression of MMP-2, XIAP,OPN and VEGF	Clinical trialNA	PMID22569271
IDOV_2560	Virus nameAdenovirus	Virus strainSG600-IL-24+IFN	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of IL-24 gene and addition of IN	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene and IFN gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line1000 cells	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result35.2% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombined therapy increases STAT1, SOCS1 and apoptosis	Immunogenic effectCombined therapy decreases expression of MMP-2, XIAP,OPN and VEGF	Clinical trialNA	PMID22569271
IDOV_2561	Virus nameAdenovirus	Virus strainSG600-IL-24+IFN	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of IL-24 gene and addition of IN	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene and IFN gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line1000 cells	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result17.7% cell survival after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombined therapy increases STAT1, SOCS1 and apoptosis	Immunogenic effectCombined therapy decreases expression of MMP-2, XIAP,OPN and VEGF	Clinical trialNA	PMID22569271
IDOV_2588	Virus nameAdenovirus	Virus strainAd.enAFP-E1A-delta-E1B-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1A, E1B and addition of AFP and IL-24	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman liver cancer cell line	Cell lineHepG2	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result10% cells are viable after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectUpregulation of GADD34	Clinical trialNA	PMID22790965
IDOV_2665	Virus nameMeasles virus	Virus strainMV-Edm	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationInsertion of human CEA gene upstream of MV N gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatoblastoma cell line	Cell lineHepG2	Concentration of cell line2.0E+5 cells per well	In-vitro toxicityNA	AssayCell proliferation assay kit	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectIncrease expression of CD46	Clinical trialNA	PMID23009685
IDOV_2666	Virus nameMeasles virus	Virus strainMV-Edm	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationInsertion of human CEA gene upstream of MV N gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatoblastoma cell line	Cell lineHepG2	Concentration of cell line2.0E+5 cells per well	In-vitro toxicityNA	AssayCell proliferation assay kit	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectIncrease expression of CD46	Clinical trialNA	PMID23009685
IDOV_2667	Virus nameMeasles virus	Virus strainMV-Edm	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationInsertion of human CEA gene upstream of MV N gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatoblastoma cell line	Cell lineHepG2	Concentration of cell line2.0E+5 cells per well	In-vitro toxicityNA	AssayCell proliferation assay kit	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectIncrease expression of CD46	Clinical trialNA	PMID23009685
IDOV_2668	Virus nameMeasles virus	Virus strainMV-Edm	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationInsertion of human CEA gene upstream of MV N gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatoblastoma cell line	Cell lineHepG2	Concentration of cell line2.0E+5 cells per well	In-vitro toxicityNA	AssayCell proliferation assay kit	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectIncrease expression of CD46	Clinical trialNA	PMID23009685
IDOV_2669	Virus nameMeasles virus	Virus strainMV-Edm	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationInsertion of human CEA gene upstream of MV N gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatoblastoma cell line	Cell lineHepG2	Concentration of cell line2.0E+5 cells per well	In-vitro toxicityNA	AssayCell proliferation assay kit	In-vitro virus concentration0.1 MOI	In-vitro result100% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectIncrease expression of CD46	Clinical trialNA	PMID23009685
IDOV_2670	Virus nameMeasles virus	Virus strainMV-Edm	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationInsertion of human CEA gene upstream of MV N gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatoblastoma cell line	Cell lineHepG2	Concentration of cell line2.0E+5 cells per well	In-vitro toxicityNA	AssayCell proliferation assay kit	In-vitro virus concentration0.1 MOI	In-vitro result90% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectIncrease expression of CD46	Clinical trialNA	PMID23009685
IDOV_2671	Virus nameMeasles virus	Virus strainMV-Edm	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationInsertion of human CEA gene upstream of MV N gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatoblastoma cell line	Cell lineHepG2	Concentration of cell line2.0E+5 cells per well	In-vitro toxicityNA	AssayCell proliferation assay kit	In-vitro virus concentration0.1 MOI	In-vitro result80% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectIncrease expression of CD46	Clinical trialNA	PMID23009685
IDOV_2672	Virus nameMeasles virus	Virus strainMV-Edm	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationInsertion of human CEA gene upstream of MV N gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatoblastoma cell line	Cell lineHepG2	Concentration of cell line2.0E+5 cells per well	In-vitro toxicityNA	AssayCell proliferation assay kit	In-vitro virus concentration0.1 MOI	In-vitro result60% cell survival after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectIncrease expression of CD46	Clinical trialNA	PMID23009685
IDOV_2673	Virus nameMeasles virus	Virus strainMV-Edm	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationInsertion of human CEA gene upstream of MV N gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatoblastoma cell line	Cell lineHepG2	Concentration of cell line2.0E+5 cells per well	In-vitro toxicityNA	AssayCell proliferation assay kit	In-vitro virus concentration1 MOI	In-vitro result90% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectIncrease expression of CD46	Clinical trialNA	PMID23009685
IDOV_2674	Virus nameMeasles virus	Virus strainMV-Edm	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationInsertion of human CEA gene upstream of MV N gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatoblastoma cell line	Cell lineHepG2	Concentration of cell line2.0E+5 cells per well	In-vitro toxicityNA	AssayCell proliferation assay kit	In-vitro virus concentration1 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectIncrease expression of CD46	Clinical trialNA	PMID23009685
IDOV_2675	Virus nameMeasles virus	Virus strainMV-Edm	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationInsertion of human CEA gene upstream of MV N gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatoblastoma cell line	Cell lineHepG2	Concentration of cell line2.0E+5 cells per well	In-vitro toxicityNA	AssayCell proliferation assay kit	In-vitro virus concentration1 MOI	In-vitro result70% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectIncrease expression of CD46	Clinical trialNA	PMID23009685
IDOV_2676	Virus nameMeasles virus	Virus strainMV-Edm	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationInsertion of human CEA gene upstream of MV N gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatoblastoma cell line	Cell lineHepG2	Concentration of cell line2.0E+5 cells per well	In-vitro toxicityNA	AssayCell proliferation assay kit	In-vitro virus concentration1 MOI	In-vitro result50% cell survival after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectIncrease expression of CD46	Clinical trialNA	PMID23009685
IDOV_2689	Virus nameMeasles virus	Virus strainMV-Edm	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationInsertion of human CEA gene upstream of MV N gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatoblastoma cell line	Cell lineHepG2	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismNude mice xenograft for Hep2G (5.0E+6 cell)	In-vivo virus concentration1.0E+7 TCID50	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 300mm after 37 days as compared to control 550mm and increase in survival time above 120 days as compared to control 30 days	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectIncrease expression of CD46	Clinical trialNA	PMID23009685
IDOV_3057	Virus nameVaccinia virus	Virus strainDeltaJ2R/FCU1 VACV	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻⁴ MOI	In-vitro result18% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3058	Virus nameVaccinia virus	Virus strainDeltaJ2R/FCU1 VACV	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻³ MOI	In-vitro result1% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3059	Virus nameVaccinia virus	Virus strainDeltaJ2R/FCU1 VACV	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻² MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3087	Virus nameVaccinia virus	Virus strainDeltaJ2R-I4L/FCU1 VACV (TG6002)	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R and I4L gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻⁴ MOI	In-vitro result15% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3088	Virus nameVaccinia virus	Virus strainDeltaJ2R-I4L/FCU1 VACV (TG6002)	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R and I4L gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻³ MOI	In-vitro result1% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3089	Virus nameVaccinia virus	Virus strainDeltaJ2R-I4L/FCU1 VACV (TG6002)	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R and I4L gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻² MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3111	Virus nameVaccinia virus	Virus strainDeltaJ2R/FCU1 VACV	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R gene and insertion of gene FCU1	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with 5-FC (200mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBD62 mice xenograft for Lovo cell line	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume decreases to below 1500 mm after 50 days	Mode of deliveryIntravenous	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3112	Virus nameVaccinia virus	Virus strainDeltaJ2R-I4L/FCU1 VACV (TG6002)	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R and I4L gene and insertion of gene FCU1	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with 5-FC (200mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBD62 mice xenograft for Lovo cell line	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume decreases to below 1000 mm after 50 days	Mode of deliveryIntravenous	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3623	Virus nameMeasles virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman liver cancer cell line	Cell lineHepG2	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result60% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3624	Virus nameMeasles virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman liver cancer cell line	Cell lineHepG2	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result20% cell viability after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3637	Virus nameMumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman liver cancer cell line	Cell lineHepG2	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3638	Virus nameMumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman liver cancer cell line	Cell lineHepG2	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell viability after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3651	Virus nameMeasles and mumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationMeasles virus in combination with mumps virus	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman liver cancer cell line	Cell lineHepG2	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result70% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3652	Virus nameMeasles and mumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationMeasles virus in combination with mumps virus	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman liver cancer cell line	Cell lineHepG2	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result18% cell viability after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_4319	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma	Cell lineHepG2	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 pfu	In-vitro result88.6 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_5205	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJCRB cell bank	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell lineNA	In-vitro toxicityToxic to normal human cell line above 10 MOI	AssayAlamar blue assay	In-vitro virus concentration2 MOI	In-vitro result100% cell viable after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27760834
IDOV_5206	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJCRB cell bank	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell lineNA	In-vitro toxicityToxic to normal human cell line above 10 MOI	AssayAlamar blue assay	In-vitro virus concentration2 MOI	In-vitro result100% cell viable after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27760834
IDOV_5207	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJCRB cell bank	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell lineNA	In-vitro toxicityToxic to normal human cell line above 10 MOI	AssayAlamar blue assay	In-vitro virus concentration2 MOI	In-vitro result80% cell viable after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27760834
IDOV_5208	Virus nameAdenovirus	Virus strainTRAD-shLuc	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having shorthairpin RNA for Luciferase gene knockout	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJCRB cell bank	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell lineNA	In-vitro toxicityToxic to normal human cell line above 10 MOI	AssayAlamar blue assay	In-vitro virus concentration2 MOI	In-vitro result100% cell viable after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27760834
IDOV_5209	Virus nameAdenovirus	Virus strainTRAD-shLuc	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having shorthairpin RNA for Luciferase gene knockout	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJCRB cell bank	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell lineNA	In-vitro toxicityToxic to normal human cell line above 10 MOI	AssayAlamar blue assay	In-vitro virus concentration2 MOI	In-vitro result100% cell viable after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27760834
IDOV_5210	Virus nameAdenovirus	Virus strainTRAD-shLuc	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having shorthairpin RNA for Luciferase gene knockout	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJCRB cell bank	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell lineNA	In-vitro toxicityToxic to normal human cell line above 10 MOI	AssayAlamar blue assay	In-vitro virus concentration2 MOI	In-vitro result80% cell viable after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27760834
IDOV_5211	Virus nameAdenovirus	Virus strainTRAD-shDICER	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having shorthairpin RNA for DICER	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJCRB cell bank	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell lineNA	In-vitro toxicityToxic to normal human cell line above 10 MOI	AssayAlamar blue assay	In-vitro virus concentration2 MOI	In-vitro result100% cell viable after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27760834
IDOV_5212	Virus nameAdenovirus	Virus strainTRAD-shDICER	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having shorthairpin RNA for DICER	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJCRB cell bank	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell lineNA	In-vitro toxicityToxic to normal human cell line above 10 MOI	AssayAlamar blue assay	In-vitro virus concentration2 MOI	In-vitro result80% cell viable after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27760834
IDOV_5213	Virus nameAdenovirus	Virus strainTRAD-shDICER	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having shorthairpin RNA for DICER	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJCRB cell bank	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell lineNA	In-vitro toxicityToxic to normal human cell line above 10 MOI	AssayAlamar blue assay	In-vitro virus concentration2 MOI	In-vitro result20% cell viable after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27760834
IDOV_5334	Virus nameNewcastle disease virus	Virus strainNDV/Anh-TRAIL	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationVirus insertion for TRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineChina Xiehe Medical University	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result56.7% cells remain viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectCaspase 3 pathway are activated	Clinical trialNA	PMID28246027
IDOV_5335	Virus nameNewcastle disease virus	Virus strainNDV/Anh-TRAIL	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationVirus insertion for TRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineChina Xiehe Medical University	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result43.2% cells remain viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectCaspase 3 pathway are activated	Clinical trialNA	PMID28246027
IDOV_5336	Virus nameNewcastle disease virus	Virus strainNDV/Anh-TRAIL	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationVirus insertion for TRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineChina Xiehe Medical University	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result29.6% cells remain viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectCaspase 3 pathway are activated	Clinical trialNA	PMID28246027
IDOV_5337	Virus nameNewcastle disease virus	Virus strainNDV/Anh-TRAIL	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationVirus insertion for TRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineChina Xiehe Medical University	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHepG2	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result20.8% cell growth inhibition	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis as measured by TUNEL assay	Immunogenic effectCaspase 3 pathway are activated	Clinical trialNA	PMID28246027